Clinical Trial Update: A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety of continued aducanumab dosing in participants with asymptomatic amyloid-related imaging abnormalities; study terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Dysfunction

Drugs mentioned

• Aducanumab (aducanumab)

Snippet

Sponsor: Biogen | Conditions: Cognitive Dysfunction, Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-09-16